<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364607</url>
  </required_header>
  <id_info>
    <org_study_id>MS.19.12.937.R1</org_study_id>
    <nct_id>NCT04364607</nct_id>
  </id_info>
  <brief_title>IM Neostigmine for Accelerating Bladder Emptying After CS by Spinal Anesthesia</brief_title>
  <official_title>Intramuscular Neostigmine for Accelerating Bladder Emptying After Cesarean Section by Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effectiveness of intramuscular (IM) 0.5 mg&#xD;
      neostigmine for accelerating bladder emptying and preventing postoperative urine retention&#xD;
      (POUR) after cesarean section (CS) performed under spinal anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women will be allowed to drink clear fluid up to 200 ml until 2 hours before induction of&#xD;
      anesthesia. All women will be asked to urinate before transfer to the operating theatre. On&#xD;
      arrival of the patient to operative theatre, intravenous (IV) cannula will be inserted and IV&#xD;
      infusion of Ringer's acetate (20 ml/kg) will be given as a fluid preload. All participants&#xD;
      will receive the standard intraoperative care and monitoring. After surgery, in the&#xD;
      postoperative care unit, participants will receive either 0.5 mg IM neostigmine (study group)&#xD;
      or IM NaCl 0.9% (control group).&#xD;
&#xD;
      Urinary bladder ultrasound will be performed hourly until spontaneous micturition occurs. If&#xD;
      POUR occurred (inability to void with at a bladder volume &gt; 600 ml detected by ultrasound),&#xD;
      then they will be catheterized by closed envelope technique. The prolate ellipsoid method was&#xD;
      used to measure urinary bladder volume based on the formula volume = length × width × height&#xD;
      × 0.52 on a two-dimensional image. The duration of surgery, the amount of administered&#xD;
      intraoperative fluid, and the urinary bladder volume before IM injection will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first voiding after IM injection</measure>
    <time_frame>Until 12 hours postoperatively</time_frame>
    <description>Time interval between IM injection of neostigmine or NaCl and occurrence of first voiding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first voiding after spinal anesthesia</measure>
    <time_frame>Until 12 hours postoperatively</time_frame>
    <description>Time interval between induction of spinal anesthesia and occurrence of first voiding</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>Neostigmine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After surgery, in the postoperative care unit, participants will receive 0.5 mg IM neostigmine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After surgery, in the postoperative care unit, participants will receive IM NaCl 0.9% as a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Participants will receive 0.5 mg IM neostigmine</description>
    <arm_group_label>Neostigmine group</arm_group_label>
    <other_name>Epistigmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>Participants will receive IM NaCl 0.9% as a placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women undergoing elective CS under spinal anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 20 or &gt; 35 years.&#xD;
&#xD;
          -  Height &lt; 150 or &gt; 180 cm or body mass index (BMI) &gt; 35 kg/m2.&#xD;
&#xD;
          -  Active labor.&#xD;
&#xD;
          -  Multifetal pregnancy.&#xD;
&#xD;
          -  Fetal distress.&#xD;
&#xD;
          -  Placenta previa.&#xD;
&#xD;
          -  Vaginal bleeding or placental abruption.&#xD;
&#xD;
          -  Medical conditions complicating or co-existing with pregnancy such as HELLP syndrome,&#xD;
             thrombocytopenia, hepatic or renal impairment, cardiac disease or pulmonary edema or&#xD;
             cyanosis.&#xD;
&#xD;
          -  Urinary tract symptoms (frequency incontinence, enuresis. nocturia, hesitancy,&#xD;
             urgency, weak stream, dysuria, and inability to empty the bladder fully).&#xD;
&#xD;
          -  Contraindication for central neuraxial block.&#xD;
&#xD;
          -  History of adverse reaction contraindications for Neostigmine.&#xD;
&#xD;
          -  Refusal to undergo regional anesthesia.&#xD;
&#xD;
          -  Surgical duration &gt; 1 hour.&#xD;
&#xD;
          -  Intraoperative significant bleeding (&gt; 10% of blood volume).&#xD;
&#xD;
          -  Any postoperative complications as eclampsia.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aml Aljaml</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nermeen M Shams-Eldien, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed S Abdelhafez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed A Elnegery, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed S Abdelhafez, MD</last_name>
    <phone>+201144523366</phone>
    <email>msabdelhafez@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura University Hospital</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cesarean Section</keyword>
  <keyword>Spinal anesthesia</keyword>
  <keyword>Postoperative urine retention (POUR)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After publication and forever</ipd_time_frame>
    <ipd_access_criteria>Contact to corresponding author</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

